Table 1 |
||||
|
Anti-MCV, anti-CCP, and IgM-RF antibodies in the control patients according to the diagnosis |
||||
|
Number (percentage) of patients with positive antibodies |
||||
|
Anti-MCV |
Anti-CCP |
IgM-RF |
||
|
|
||||
|
Cutoff 20 U/mL |
Cutoff 28 U/mL |
|||
|
|
||||
|
Psoriatic arthritis (n = 51) |
6 (11.8) |
5 (9.8) |
5 (9.8) |
5 (9.8) |
|
Primary Sjögren syndrome (n = 58) |
6 (10.3) |
6 (10.3) |
6 (10.3) |
15 (25.8) |
|
Ankylosing spondylitis (n = 49) |
3 (6.1) |
2 (4.1) |
1 (2) |
1 (2) |
|
Healthy controls (n = 50) |
5 (10) |
0 (0) |
0 (0) |
0 (0) |
|
Total (n = 208) |
20 (9.6) |
13 (6.2) |
12 (5.8) |
21 (10.1) |
|
|
||||
|
Anti-CCP, anti-cyclic citrullinated peptide antibody; anti-MCV, anti-mutated vimentin citrullinated antibody; RF, rheumatoid factor. |
||||
|
Nicaise Roland et al. Arthritis Research & Therapy 2008 10:R142 doi:10.1186/ar2570 |
||||
